moxidectin / Generic mfg. - LARVOL DELTA

The most effective systemic treatment in cats with otodectic mange: A critically appraised topic. (PubMed, Can Vet J) - "Isoxazolines (sarolaner, fluralaner, or esafoxolaner) or similar molecules such as tigolaner (a bispyrazole) and macrocyclic lactones (selamectin, eprinomectin, or moxidectin) can lead to parasitological cure and improvement of clinical signs associated with otodectic mange in cats, with rare, mainly cutaneous side effects with mild, autoresolving lesions. Similarities in the clinical and parasitological efficacy of these substances highlight the need for comparative studies that could allow identification of the most efficacious product."

Journal • Review • Otorhinolaryngology

Development of impact resistant immediate release amorphous solid dispersion via hot-melt extrusion and injection molding. (PubMed, Int J Pharm) - "Moxidectin, a low-dosage, high-potency BCS class II drug was used as a model API for formulation development...Placebo and API-loaded formulations were extruded and injection molded into circular and unique geometries using molds produced by stereolithography. Lastly, the HME-IM tablet formulations were observed to be extremely tough and would be an excellent candidate in the production of abuse-deterrent formulations for controlled substances."

Journal

Feline Cryptococcosis due to Cryptococcus gattii VGII (Recently Renamed as C. deuterogattii) in an FIV-Positive Cat With Demodicosis From Manaus, Central Amazon, Brazil. (PubMed, Case Rep Vet Med) - "The cat was treated with fluconazole (10 mg/kg/day) and topical fluralaner-moxidectin, resulting in complete clinical resolution of all lesions and associated symptoms. This report underscores the significance of considering cryptococcosis as a differential diagnosis in immunocompromised cats presenting with cutaneous or respiratory symptoms. Additionally, it highlights the importance of recognizing the Amazon region as an area of environmental prevalence of C. gattii VGII, reinforcing the need for awareness regarding its impact on animal health."

Journal

Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care. (PubMed, Pharmaceutics) - "Some remarkable LAI products, such as ProHeart® (moxidectin), Excede® (ceftiofur), and POSILACTM (recombinant bovine somatotropin), show clinical relevance and commercial success...Additionally, challenges in characterization, in vitro testing, in vitro in vivo correlation (IVIVC), and safety concerns regarding biocompatibility are discussed, along with the prospects for next-generation LAIs. Continued advancement in the field of LAI in veterinary medicine is essential for improving animal health."

Journal • Review

Evaluation of nematode susceptibility and resistance to anthelmintic drugs with a WMicrotracker motility assay. (PubMed, Sci Rep) - "Additionally, cross-resistance assessment showed that IVR10 exhibited decreased sensitivity to moxidectin (MOX) and eprinomectin (EPR) relative to N2B...Our findings demonstrate, for the first time, the relevance of WMA as a phenotypic assay for detecting ML resistance in nematodes by measuring their motility response. This research sheds light on a novel approach for monitoring drug resistance, vital for effective parasite management strategies."

Journal • Infectious Disease

Cost-Effectiveness of Treatment for Canine Parasites in Remote Indigenous Communities. (PubMed, Ecohealth) - "We compared canine parasite treatments in a Torres Strait Islander community setting, including oxibendazole/praziquantel tablets (OXI), moxidectin/imidacloprid spot-on (MOX), off-label oral ivermectin (IVM), afoxolaner chews (AFO), and flumethrin/imidacloprid collars (FLU). Sensitivity analyses supported these results. This study contributes cost-effectiveness data to inform parasite treatment program policy with aims of significant reductions in zoonotic canine parasite prevalence and subsequent reductions in environmental contamination with infectious parasite stages."

HEOR • Journal • Infectious Disease

Overexpression of the Wbl family regulator whiDsbh modulates secondary metabolite biosynthesis in Streptomyces. (PubMed, World J Microbiol Biotechnol) - "Overexpression of whiDsbh in BC04 significantly suppressed milbemycin production by repressing the transcription of the milbemycin biosynthetic gene cluster via the ActK/R-KelR regulatory cascade...noncyanogenus and Streptomyces caniferus, respectively. These results expanded our understanding of the regulatory networks controlling SM biosynthesis in Streptomyces and provided beneficial regulatory targets for developing strategies to optimize SM yield."

Journal

Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trial. (PubMed, Lancet Infect Dis) - P3 | "In this study, single-dose MoxA was superior to IA for W bancrofti microfilaria clearance at 12 months and provided prolonged microfilaria clearance for most participants. These results suggest that MoxA could be a powerful tool to accelerate the elimination of lymphatic filariasis in Africa."

Journal • Inflammation

Efficacy and Safety Study of Moxidectin in Adults With Scabies (clinicaltrials.gov) - P2 | N=200 | Completed | Sponsor: Medicines Development for Global Health | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

Efficacy of Simparica Trio® against induced infections of Ancylostoma braziliense and Ancylostoma ceylanicum in dogs. (PubMed, Parasit Vectors) - "Simparica Trio® containing sarolaner, moxidectin and pyrantel was highly effective against induced infections of L4, L5 and adult stages of A. braziliense and the adult stage of A. ceylanicum in dogs."

Journal • Infectious Disease

Safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) in homozygous MDR1-mutant collie dogs. (PubMed, Parasit Vectors) - "Credelio Quattro was well tolerated and is safe in MDR1 mutant dogs up to 5× the maximum recommended dose following three consecutive monthly administrations."

Journal • Ataxia • CNS Disorders • Depression • Epilepsy • Movement Disorders • Ophthalmology • Psychiatry • ABCB1

The ability of an oral combination of afoxolaner, moxidectin and pyrantel to protect dogs from Borrelia burgdorferi infections transmitted by Ixodes scapularis. (PubMed, Parasit Vectors) - "The results of these studies indicate that NexGard® Plus administered at a dose close to the minimum recommended dose of 2.5 mg/kg afoxolaner is effective 28 days after a single treatment in the prevention of B. burgdorferi transmission from naturally infected I. scapularis ticks to dogs."

Journal • Infectious Disease • Inflammatory Arthritis • Lyme Disease

Mycobacterium susceptibility to ivermectin by inhibition of eccD3, an ESX-3 secretion system component. (PubMed, PLoS Comput Biol) - "According to the in silico results, selamectin, avermectin, ivermectin, and moxidectin were selected as prospective drugs...Blockage of EccD3 increased the ivermectin action, but the modest changes observed may be explained by the compensatory mechanisms or other ivermectin targets in absence of this Esx3 component. Further in vitro and preclinical studies are required to validate our findings."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Moxidectin unravels the role of Hippo-YAP pathway in maintaining immunity of glioblastoma multiforme. (PubMed, Mol Cancer Ther) - "Inhibition of MEK-ERK by moxidectin ultimately led to blockade of the nuclear translocation and transcriptional activity of YAP/TAZ-TEAD complex in various GBM cells. Chronic moxidectin treatment did not cause any toxicity in mice based on our toxicological evaluation. Moxidectin is an FDA approved drug, findings from our study will promote its clinical investigation as a potential therapeutic agent for GBM patients."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) in dogs infected with adult heartworms (Dirofilaria immitis). (PubMed, Parasit Vectors) - "Credelio Quattro, when administered at 1× and 3× the maximum recommended label dose, was well tolerated following three consecutive monthly administrations to heartworm-positive dogs. Although Credelio Quattro caused a rapid reduction in microfilaria counts, no adverse effects related to microfilaria reduction were observed, and there was no effect on adult worms in this study."

Journal • Immunology • Infectious Disease

Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of hookworm infections in dogs. (PubMed, Parasit Vectors) - "Credelio Quattro, a novel oral chewable tablet administered at the minimum effective dosages of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5.0 mg/kg praziquantel, and 5.0 mg/kg pyrantel (as pamoate salt), was safe and effective for the treatment and control of L4, immature adult, and adult stages of A. caninum and adult U. stenocephala in dogs."

Journal • Infectious Disease

Treatment and control of Haemaphysalis longicornis infestations on dogs using a formulation of sarolaner, moxidectin and pyrantel (Simparica Trio®). (PubMed, Parasit Vectors) - "A single administration of Simparica Trio at minimum label dose was efficacious in treating and controlling adult H. longicornis in dogs for more than one month."

Journal

Severe respiratory distress in a stray cat caused by the lungworm Aelurostrongylus abstrusus: A first case report in Lithuania. (PubMed, Vet Parasitol Reg Stud Reports) - "The L1 of A. abstrusus were still present in the faeces 3 weeks, and cough persisted 4 weeks following the first treatment with moxidectin; anthelmintic treatment was therefore continued with a fipronil/praziquantel/eprinomectin spot-on solution (Broadline®; Boehringer Ingelheim/Merial) according to manufacturer's instructions. No L1 of A. abstrusus were present in the faeces 7 weeks and cough disappeared 11 weeks following the first treatment with moxidectin."

Journal • Cough • Eosinophilia • Hematological Disorders • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Comparison of the initial and residual speed of Amblyomma americanum kill on dogs treated with a single dose of Bravecto® Chew (25 mg/kg fluralaner) or Simparica TRIO® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel). (PubMed, Parasit Vectors) - "Amblyomma americanum infestations are controlled more quickly immediately upon treatment and at 21, 28, and 35 days post-treatment for Bravecto® compared with Simparica TRIO®-treated dogs."

Clinical • Journal

Resistance of Rhipicephalus microplus to different acaricides in tropical climates: Are the laboratory and field results related? (PubMed, Vet Parasitol) - "For the field assays, the same commercial products of the AIT used, a pour-on formulation of fipronil 1 mg/kg, injectable 200 µg/kg ivermectin, injectable 630 µg/kg ivermectin, injectable 200 µg/kg doramectin and injectable 200 µg/kg moxidectin...This approach will allow for more accurate recommendations regarding the use of a chemical formulation for a specific tick population. Furthermore, it reduces the risk of incorrectly identifying R. microplus population as resistant or susceptible and helps clarify the practical implications of resistance."

Journal

Model development to assess the impact of a preventive treatment with sarolaner and moxidectin on Dirofilaria immitis infection dynamics in dogs. (PubMed, Parasit Vectors) - "The preventive efficacy, as measured by the number of non-infected dogs, increases with increasing treatment compliance, but the extent of the treatment effect differs with the epidemiological setting. Adding sarolaner to a heartworm prevention has a complimentary impact on mosquito survival and heartworm disease transmission, although this effect depends on the epidemiological settings, emphasizing the true complexity of disease dynamics of a vector-borne disease."

Journal • Infectious Disease

Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of Echinococcus multilocularis and E. granulosus infections in dogs. (PubMed, Parasit Vectors) - "Credelio Quattro administered once orally at the minimum dosages of 20 mg/kg of lotilaner, 0.02 mg/kg of moxidectin, 5.0 mg/kg of praziquantel and 5.0 mg/kg of pyrantel was safe and effective for the treatment and control of adult E. granulosus and E. multilocularis in dogs."

Journal • Infectious Disease

Eucoleus aerophilus (syn. Capillaria aerophila) infection in zoo-housed arctic foxes (Vulpes lagopus). (PubMed, Acta Parasitol) - "We here show clinical and necropsy data and morphological and molecular worm identifications and call for further parasitological research in ex situ populations of arctic foxes to assess the impact of parasites on this species."

Journal • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Efficacy of a topical formulation combining fipronil, moxidectin, and praziquantel (Banni3) in controlling flea infestation in cats. (PubMed, Front Vet Sci) - "There was no statistically significant difference (P > 0.05) when comparing flea counts between the treated group and positive control, but there were statistically significant differences (P < 0.05) in the pre- and post-treatment evaluations. A topical treatment with Banni3, administered as a single dose, is proven safe and effective for controlling C. felis felis in artificially and naturally infested cats."

Journal

Laboratory evaluation of drugs/systemic insecticides as endectocides through membrane feeding method: a unique approach for the control of mosquito vectors. (PubMed, Pest Manag Sci) - "Application of these drugs in livestock could provide an added advantage, as an attract-feed-kill method, to existing vector control tools."

Journal